What does research say about ayahuasca and PTSD?

Does ayahuasca help with PTSD?

No controlled trial has shown that ayahuasca helps with PTSD. The most-cited evidence is an uncontrolled case series of eight military veterans in a three-day ayahuasca intervention, later corrected in 2024, whose reliable-change estimate was revised from 87.5% to 71.4% on the PCL-5 checklist, with 5 of 7 veterans maintaining changes at three months.

The case series, published in Psychological Trauma in December 2024 with electronic publication on December 7, 2023, was a convergent mixed-methods design without a control group, so it cannot isolate ayahuasca from the retreat program, expectations, or other life changes. The authors themselves describe it as preliminary support only. The Cleveland Clinic states ayahuasca is not recommended for medicinal or therapeutic use at this time.

Among psychedelics, MDMA-assisted therapy, not ayahuasca, has the strongest PTSD evidence: the VA National Center for PTSD states two randomized placebo-controlled phase 3 trials of the Lykos protocol demonstrated treatment efficacy with large effect sizes. Clinical trials without psychotherapy, including a comparison of ayahuasca with esketamine, are ongoing at a Brazilian laboratory, per a published review. Readers can confirm current trials on ClinicalTrials.gov.

Sources, checked November 15, 2026: Ayahuasca in the treatment of posttraumatic stress disorder:..., Ayahuasca: What It Is and Risks, Psychedelic-Assisted Therapy for PTSD - PTSD: National Center for PTSD, Ayahuasca: pharmacology, safety, and therapeutic effects - PMC

What are the risks of ayahuasca for someone with PTSD?

Ayahuasca carries real risks for people with PTSD: about 70% of more than 10,000 Global Ayahuasca Survey respondents reported physical side effects, mostly nausea and vomiting, 55.9% reported adverse mental health effects in the weeks or months after use, and among respondents with diagnosed anxiety, 2.7% considered their symptoms worsened by ayahuasca. People on SSRIs face a serotonin syndrome risk.

• SSRIs and other serotonin-raising medications: the Cleveland Clinic warns the combination risks serotonin syndrome, which can be mild to life-threatening.
• History of psychosis, schizophrenia or anxiety conditions: the Alcohol and Drug Foundation states ayahuasca can trigger or worsen these conditions and advises avoidance.
• Cardiovascular conditions: ayahuasca produces moderate transient increases in blood pressure and heart rate, probably via the 5-HT2A receptor.
• Combining substances: fatalities have been reported when harmala alkaloids were combined with MDMA, LSD, psilocybin and 5-MeO-DMT.
• Unexamined trauma: a prospective study of 40 ceremony participants found 7 with extremely challenging psychological reactions, 4 of whom had prior psychiatric diagnoses.

A case report describes a generalized anxiety disorder patient with heightened anxiety and panic for weeks after a ceremony who needed medical intervention. Retreat settings vary widely. The Alcohol and Drug Foundation advises verifying screening processes, emergency protocols, proximity to medical care and supervision arrangements before attending. ICEERS offers free screening questionnaires (AyaSafe 2) and up to five free integration sessions through its El Faro Support Center. This is general information, not medical advice; medication and eligibility questions belong with a licensed clinician.

Sources, checked November 15, 2026: Ayahuasca: What It Is and Risks, Adverse effects of ayahuasca: Results from the Global Ayahuasca..., Ayahuasca and Dimethyltryptamine Adverse Events and Toxicity..., Ayahuasca - Alcohol and Drug Foundation, Ayahuasca: pharmacology, safety, and therapeutic effects - PMC

How does ayahuasca affect trauma memory in the brain?

No established mechanism links ayahuasca to PTSD symptom relief. What is documented is pharmacology: DMT in ayahuasca acts on serotonin 5-HT2A receptors and sigma-1 receptors, and ayahuasca produces moderate transient increases in blood pressure, heart rate and stress hormones. Any connection between these effects and trauma memory is a proposed research question, not a demonstrated therapeutic mechanism.

A SPECT study of 15 male volunteers found ayahuasca activated frontal and paralimbic brain regions and increased blood perfusion bilaterally in the anterior insula. That is a finding about brain activity during acute effects in healthy volunteers, not evidence about fear extinction, memory reconsolidation or trauma processing in people with PTSD. How ayahuasca might relate to trauma symptoms remains an open research question.

Sources, checked November 15, 2026: Ayahuasca: A review of historical, pharmacological, and therapeutic..., Rapid antidepressant effects of the psychedelic ayahuasca in..., Ayahuasca: pharmacology, safety, and therapeutic effects - PMC, Ayahuasca: Psychological and Physiologic Effects, Pharmacology and...

What PTSD treatments have better evidence than ayahuasca?

The VA National Center for PTSD reports two positive randomized phase 3 trials of MDMA-assisted therapy with large effect sizes, while the most-cited ayahuasca evidence is a corrected case series of eight veterans.

MDMA and psilocybin remain Schedule I substances. Few veterans were included in the phase 3 MDMA studies, about 19% of each sample, which the VA notes limits generalizability to veterans. Anyone weighing options should discuss evidence and personal history with a licensed clinician rather than changing current PTSD care because of ayahuasca reports.

Sources, checked November 15, 2026: Psychedelic-Assisted Therapy for PTSD - PTSD: National Center for PTSD, Ayahuasca in the treatment of posttraumatic stress disorder:...

Can ayahuasca be used to treat PTSD?

Not as an established treatment. A PubMed-indexed review describes ayahuasca, a plant-based psychedelic, as discussed as promising for PTSD treatment, and researchers in Brazil report that clinical trials assessing ayahuasca for PTSD are ongoing at their laboratory. Promise under study is different from approved, proven therapy. What exists today are small observational reports, not controlled efficacy trials for PTSD.

For comparison, the strongest psychedelic evidence in PTSD belongs to MDMA-assisted therapy. The VA National Center for PTSD reports that two randomized placebo-controlled phase 3 trials of the Lykos MDMA protocol demonstrated treatment efficacy with large effect sizes, while ayahuasca has nothing comparable for PTSD. The VA also notes MDMA and psilocybin are the most studied psychedelics to date.

Sources: Ayahuasca in the treatment of posttraumatic stress disorder:..., Ayahuasca: pharmacology, safety, and therapeutic effects - PMC, Psychedelic-Assisted Therapy for PTSD - PTSD: National Center for PTSD

Which psychedelics are helping veterans?

According to the VA National Center for PTSD, MDMA-assisted therapy is the psychedelic approach being researched to augment PTSD treatment, and it is the one with the strongest veteran-relevant evidence base. MDMA remains a Schedule I substance, defined as a drug with high abuse potential and no currently accepted medical use, and in August 2024 the FDA declined to approve MDMA-assisted therapy and asked for an additional phase 3 trial.

The VA page also describes a survey of U.S. Special Forces veterans who received ibogaine and 5-MeO-DMT at a clinical program in Mexico, which reported substantial improvement in PTSD symptoms and suicidal ideation after the program. That is a survey, not a controlled trial. On psilocybin, the VA states there is currently no published data on psilocybin for treating PTSD itself, though research on co-occurring depression and anxiety continues.

Sources: Psychedelic-Assisted Therapy for PTSD - PTSD: National Center for PTSD

Does the VA do psychedelic therapy?

The VA does not currently provide psychedelic therapy as standard care. The VA National Center for PTSD states that MDMA and psilocybin remain Schedule I substances and describes ongoing research rather than available treatment. The Lykos psychotherapy model, the most-studied MDMA protocol, has not been studied as a stand-alone PTSD treatment and is not mentioned in the current VA/DoD Clinical Practice Guideline for PTSD.

The VA page also notes that current studies use rigorous eligibility criteria that exclude many people with PTSD, including a requirement to taper SSRIs and other psychoactive medications. A veteran interested in research participation should ask the VA about trials they may qualify for, and medication questions should go to the prescribing clinician.

Sources: Psychedelic-Assisted Therapy for PTSD - PTSD: National Center for PTSD

How does ayahuasca work in the brain?

Ayahuasca is a brew made by decocting two plants: Psychotria viridis, which contains DMT, and the Banisteriopsis caapi vine, which contains harmala alkaloids that act as monoamine oxidase inhibitors. DMT alone is not psychedelic when swallowed because gut enzymes deactivate it. The vine's MAO inhibitors keep those enzymes from destroying DMT, allowing it to reach the brain and produce a 4- to 6-hour psychedelic experience.

In controlled pharmacology studies, psychological effects typically began 30 to 60 minutes after administration, peaked between 60 and 120 minutes, and resolved by about 240 minutes. DMT acts on serotonin receptors, including 5HT2A. How these pharmacological effects might relate to trauma symptoms is a research question, not a settled mechanism.

Sources: Rapid antidepressant effects of the psychedelic ayahuasca in..., Ayahuasca Therapy Information- UC Berkeley BCSP, Ayahuasca: An ancient sacrament for treatment of contemporary..., Ayahuasca: pharmacology, safety, and therapeutic effects - PMC

Can ayahuasca help with trauma and childhood trauma specifically?

There is no published clinical trial of ayahuasca for childhood trauma or complex PTSD. What exists are self-report survey data and retrospective accounts. In the Global Ayahuasca Project survey, among 1,125 participants reporting anxiety, 90% reported improvement, including 16% who described symptoms as completely improved or resolved. Self-reported improvement after attending a ceremony cannot show that the brew caused it.

Researchers and safety advocates urge caution specifically around trauma. David Londono, speaking to ICEERS, described ayahuasca's effects on trauma as a double-edged sword, noting that while many people reprocess traumatic situations, others experience overwhelming episodes that can worsen the symptoms with which they came. Jeronimo Mazarrasa warned that memories emerging during sessions are not necessarily true or verifiable, which matters for people processing childhood memories.

A prospective longitudinal study of 40 ceremony participants found 7 with extremely challenging psychological reactions, 4 of whom had prior psychiatric diagnoses. Childhood trauma is not itself an exclusion in the research literature, but unexamined trauma combined with an unscreened ceremony setting raises the stakes of preparation and aftercare.

Sources: The Effects of Ayahuasca on Psychological Disorders: A Systematic..., Adverse effects of ayahuasca: Results from the Global Ayahuasca..., Ayahuasca in Non-native Contexts: Ethical and Safety Challenges, The Art of Integration: How to Support Ayahuasca Experiences

Who should not try ayahuasca?

Published sources consistently advise some people to avoid ayahuasca. The Alcohol and Drug Foundation states that ayahuasca can trigger or worsen conditions such as anxiety, schizophrenia or psychosis, and that anyone with a history of these issues, or with a mental health condition or family history of one, should avoid it. A review of the clinical literature concludes acute administration has an acceptable safety profile with a narrow margin and should be avoided by people with certain pre-existing mental conditions and by pregnant women.

• People with a personal or family history of psychosis, schizophrenia or mania. A case report describes a manic episode in a 30-year-old man with bipolar disorder after a four-day ayahuasca ritual.
• People taking medications that raise serotonin. The Cleveland Clinic warns combining ayahuasca with such medications risks serotonin syndrome, which can be mild to life-threatening.
• People combining substances. Fatalities have been reported when harmala alkaloids were combined with MDMA, LSD, psilocybin, 5-MeO-DMT and related compounds.
• People with cardiovascular conditions should discuss risks with a clinician, since controlled dosing raised diastolic blood pressure in healthy volunteers.

This is general information, not medical advice. Medication, diagnosis and eligibility questions belong with a licensed clinician who knows your history. ICEERS publishes free screening questionnaires, including AyaSafe 2, a health questionnaire collecting the medical history needed to identify potential contraindications.

Sources: Ayahuasca - Alcohol and Drug Foundation, Ayahuasca and Dimethyltryptamine Adverse Events and Toxicity..., Switch to mania after ayahuasca consumption in a man with bipolar..., Ayahuasca: What It Is and Risks

What are the risks for people with PTSD considering ayahuasca?

The most common physical effects are nausea and vomiting. In the Global Ayahuasca Survey of more than 10,000 people, about 70% reported physical side effects, most commonly nausea and vomiting, though only 2.3% of those reporting physical effects said they needed medical attention. Among survey respondents with diagnosed anxiety or depression, 2.7% and 4.5% respectively considered their symptoms to have worsened as a result of ayahuasca.

Psychedelic researchers warn that psychedelics can cause psychologically destabilizing consequences such as disorientation or increased sensitivity, can exacerbate mental health conditions, or can instigate new symptoms. Having an anxiety disorder significantly increased the risk of adverse mental health effects in the Global Ayahuasca Survey data. For a person with PTSD, these figures argue for medical screening, a low facilitator-to-participant ratio, and planned aftercare rather than a casual booking.

Sources: Ayahuasca: What It Is and Risks, Adverse effects of ayahuasca: Results from the Global Ayahuasca..., Ayahuasca and Dimethyltryptamine Adverse Events and Toxicity..., A landscape analysis of psychedelic retreat organizations advertising...

What is the most effective treatment for PTSD compared with ayahuasca?

Among psychedelics, the VA describes the Lykos protocol as having the greatest evidence base: twelve 90-minute therapy sessions plus three 6- to 8-hour medicine sessions, with three 90-minute preparation sessions before the first medicine session and three 90-minute integration sessions after each, tested in two randomized placebo-controlled phase 3 trials.

The comparison table shows why a reader should be wary of any retreat marketing ayahuasca as PTSD treatment. See our depression research page for the stronger ayahuasca evidence base, and our comparison of ayahuasca and psilocybin claims.

Sources: Psychedelic-Assisted Therapy for PTSD - PTSD: National Center for PTSD, Ayahuasca in the treatment of posttraumatic stress disorder:...

Is ayahuasca legal in the United States?

Classic psychedelics, including DMT, are Schedule I under the federal Controlled Substances Act, meaning high abuse potential and no currently accepted medical use, and DMT is also listed under the 1971 UN Convention on Psychotropic Substances. Despite this, one market study found that 29.5% of identified psychedelic retreat organizations offered retreats at a U.S. location. This is general information, not legal advice.

Religious exemptions exist in limited circumstances. The Oregon State Board of Pharmacy concluded in 2000 that ayahuasca had a nondrug use in the Santo Daime religion and was not subject to state regulation, and Health Canada authorized a Santo Daime church to import ayahuasca tea in 2006. Those rulings do not create a general legal path for therapy-seeking individuals. Details are on our U.S. legality page.

Sources: Psychedelic-Assisted Therapy for PTSD - PTSD: National Center for PTSD, A landscape analysis of psychedelic retreat organizations advertising..., Adverse effects of ayahuasca: Results from the Global Ayahuasca..., Ayahuasca: Psychological and Physiologic Effects, Pharmacology and...

What should a veteran reading Reddit threads do next?

Start with the evidence rather than testimonials, and keep your current care in place. Public Reddit threads read in November 2026 contain many personal accounts of ayahuasca helping or hurting trauma symptoms. Those accounts are real experiences, but they cannot tell you what would happen to you or what caused the change.

• Read the corrected veteran case series and its erratum together, not the original abstract alone.
• Ask the VA about psychedelic research trials you may qualify for, and discuss any interest with your VA or private clinician.
• If considering a retreat abroad, review our how to choose an ayahuasca retreat guide and the risks and screening questions page.
• Verify medical screening, facilitator training and aftercare with any provider, using our questions to ask a retreat provider.

Sources: Ayahuasca in the treatment of posttraumatic stress disorder:..., Psychedelic-Assisted Therapy for PTSD - PTSD: National Center for PTSD

Can ayahuasca help with depression that often accompanies PTSD?

Depression is where ayahuasca research is strongest, though studies remain small. One randomized controlled trial compared a single dose of ayahuasca to placebo in 29 participants with treatment-resistant depression, and an open-label trial in 17 patients found a single dose reduced depressive symptoms from the first hours until 21 days afterwards, a 61% reduction on the Hamilton scale.

Those trials involved diagnosed depression under medical supervision, not PTSD, and excluded people on antidepressants through a washout period. They do not transfer to a retreat setting or to trauma symptoms. See our dedicated depression research page for the full picture.

Sources: Ayahuasca: A review of historical, pharmacological, and therapeutic..., Ayahuasca: pharmacology, safety, and therapeutic effects - PMC, Rapid antidepressant effects of the psychedelic ayahuasca in...

What did the small veteran case series study?

Eight combat veterans participated in a three-day intervention, with assessments at baseline and following the intervention, plus a three-month follow-up. The study used an uncontrolled mixed-methods case-series design. Reported changes therefore occurred alongside an intervention that lacked a randomized comparison.

A case series can record experiences and generate research questions. It cannot isolate the contribution of the substance from other aspects of attendance, expectations or changes outside the study. Calling a report prospective describes when observations were collected. It does not give the study the causal strength of a controlled trial.

Why is the published correction essential?

The authors' PCL-5 scoring used 1-to-5 responses rather than the appropriate 0-to-4 scale. The correction states that baseline scores reflected moderate posttraumatic stress symptoms, rather than the initially claimed clinical-threshold severity. It revised the reliable-change estimate from 87.5% to 71.4% and removed a clinical-significance threshold because some participants already met it at baseline.

Read the erratum beside the original article. A numerical correction can change the population description as well as a result. Repeating the older abstract without the correction would misrepresent the evidence.

What does the newer veteran retreat study add?

A 2025 naturalistic study assessed 58 veterans attending ayahuasca or psilocybin retreats. Authors reported improvement in several self-reported mental-health and transition measures within four weeks after attendance. Participants were not randomly assigned between substances, and there was no untreated control.

That study adds an observation, not a head-to-head efficacy result. Differences between separate attendee groups may reflect differences that existed before attendance or in their circumstances. Keep population, substance, setting and outcome definitions visible when comparing the report with the smaller case series.

What remains unresolved about PTSD treatment?

A symptom checklist, a verified diagnosis and a treatment outcome are distinct. Ask who assessed the diagnosis, what counted as meaningful change and how the comparison was constructed. Also check whether a result concerns all participants or only those with available follow-up.

The studies described here leave causal effectiveness and broader applicability unresolved. They do not supply a reason to stop established PTSD care or to regard a commercial retreat as clinical treatment. A qualified professional can discuss the actual evidence alongside a person's current care. This guide cannot diagnose PTSD from a reader's history or decide eligibility.

How should veteran samples be read alongside broader PTSD questions?

Both published studies recruited military veterans, and that specificity shapes what they can show. A combat-veteran sample recruited through veteran networks has particular characteristics: service-related trauma exposure, often established care pathways, and recruitment channels connected to military communities. Results from that population cannot automatically describe civilians with PTSD, first responders, or people whose trauma history differs in type or timing.

The case series followed eight veterans through a three-day intervention with a three-month follow-up. The naturalistic study assessed 58 veterans attending ayahuasca or psilocybin retreats, reporting improvement in self-reported mental-health and transition measures within four weeks. Neither study included random assignment to an untreated comparison, and participants were not randomized between substances in the newer cohort.

This means two limits compound: the design cannot isolate the substance's contribution from attendance, expectations or concurrent life changes, and the sample cannot represent every person with posttraumatic symptoms. When a provider presents veteran results to a non-veteran audience, or a checklist score as a diagnosis, both transfers are unsupported.

The practical reading questions are: who assessed the diagnosis, what counted as meaningful change, whether results cover all participants or only those with follow-up data, and whether the reported symptom change concerns the population and timeframe being advertised. These questions apply to any future veteran study and to any civilian claim built on top of one.